GRIN2B: A Potential Drug Target and Biomarker for Neurological and Psychiatric Disorders

Target Name: GRIN2B

NCBI ID: G2904

GRIN2B

GRIN2B: A Potential Drug Target and Biomarker for Neurological and Psychiatric Disorders

G protein-coupled receptors (GRPs) are a family of transmembrane proteins that play a crucial role in cellular signaling. They are involved in various physiological processes, including sensory perception, neurotransmission, and hormone signaling. The thirdGRIN family member, GRIN2B (Neuron-Specific G protein-Coupled Receptor), is an attractive drug target and potential biomarker due to its unique function in neural circuits. In this article, we will discuss the biology of GRIN2B, its potential as a drug target, and its potential as a biomarker for various neurological and psychiatric disorders.

Background

GRPs are a family of transmembrane proteins that can modulate various cellular processes. They are involved in sensory perception, neurotransmission, and hormone signaling. The firstGRP, GRP1, was identified in 1981 and has been extensively studied ever since. It is a G protein-coupled receptor that is expressed in various tissues, including the brain. GRP1 plays a crucial role in sensory perception, including vision and hearing. It is also involved in neurotransmission, including the regulation of neurotransmitter release and uptake.

The secondGRP, GRP2, was identified in 1995 and is also a G protein-coupled receptor. It is expressed in various tissues, including the brain and is involved in neurotransmission. The thirdGRP, GRIN2B, was identified in 2004 and is also a G protein-coupled receptor. It is specifically expressed in neurons and is involved in neurotransmission.

GRIN2B is a unique GRP due to its specific function in neural circuits. It is involved in the regulation of neurotransmitter release and uptake, as well as the modulation of neuronal excitability. It is expressed in neurons and is involved in the regulation of various neural processes, including neuronal communication and synaptic plasticity.

Potential Drug Target

GRIN2B is a potential drug target due to its unique function in neural circuits. The ability to modulate neurotransmission and neuronal excitability makes it an attractive target for drugs that target neurotransmitter release and uptake. This is because drugs that can modulate neurotransmission can have a therapeutic effect on various neurological and psychiatric disorders, including depression, anxiety, and neurodegenerative diseases.

GRIN2B is also a good candidate for a biomarker for various neurological and psychiatric disorders. Its expression is highly specific to neurons and is involved in the regulation of various neural processes. This makes it an attractive biomarker for the diagnosis and treatment of neurological and psychiatric disorders.

Potential Applications

GRIN2B is an attractive drug target due to its unique function in neural circuits and its potential to modulate neurotransmission. The ability to modulate neurotransmission and neuronal excitability makes it an attractive target for drugs that target neurotransmission. This is because drugs that can modulate neurotransmission can have a therapeutic effect on various neurological and psychiatric disorders.

GRIN2B is also an attractive biomarker due to its specific function in neurons and its potential to modulate various neural processes. This makes it an attractive biomarker for the diagnosis and treatment of neurological and psychiatric disorders.

Conclusion

GRIN2B is a unique G protein-coupled receptor that is involved in the regulation of neurotransmission and neuronal excitability. Its function in neural circuits makes it an attractive drug target for the diagnosis and treatment of various neurological and psychiatric disorders. Its potential as a biomarker for these disorders makes it an attractive target for drug development. Further research is needed to fully understand the biology of GRIN2B and its potential as a drug target and biomarker.

Protein Name: Glutamate Ionotropic Receptor NMDA Type Subunit 2B

Functions: Component of NMDA receptor complexes that function as heterotetrameric, ligand-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Channel activation requires binding of the neurotransmitter glutamate to the epsilon subunit, glycine binding to the zeta subunit, plus membrane depolarization to eliminate channel inhibition by Mg(2+) (PubMed:8768735, PubMed:26919761, PubMed:26875626, PubMed:28126851). Sensitivity to glutamate and channel kinetics depend on the subunit composition (PubMed:8768735, PubMed:26875626). In concert with DAPK1 at extrasynaptic sites, acts as a central mediator for stroke damage. Its phosphorylation at Ser-1303 by DAPK1 enhances synaptic NMDA receptor channel activity inducing injurious Ca2+ influx through them, resulting in an irreversible neuronal death. Contributes to neural pattern formation in the developing brain. Plays a role in long-term depression (LTD) of hippocampus membrane currents and in synaptic plasticity (By similarity)

The "GRIN2B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GRIN2B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets